Reyon Pharmaceutical Co. Ltd. (102460)

Overview

REYON Pharmaceutical Co., Ltd., established in 1955 and headquartered in Seoul, South Korea, is a prominent player in the pharmaceutical industry. The company specializes in the manufacturing and selling of a wide range of medicines. With a diverse product portfolio that spans across various therapeutic areas, REYON Pharmaceutical Co., Ltd. has marked its presence not only in the domestic market but also in the international pharmaceutical landscape. The company is also deeply involved in pioneering research and development activities, particularly in the area of gene therapy and therapeutics antibody, reflecting its commitment to advancing medical science and improving patient care.

Products and Services

REYON Pharmaceutical Co., Ltd. offers an extensive range of products and services across various therapeutic categories:

• VM202RY: A gene therapy drug in Phase II clinical trial aimed at treating vascular neurological diseases including coronary artery disease, chronic non-healing diabetic/ischemic ulcers, diabetic neuropathy, and amyotrophic lateral sclerosis.
• VM206RY: An anti-cancer gene therapy currently under Phase I clinical trials for the treatment of breast cancer.
• RY103 [NS101]: A therapeutic antibody for Alzheimer’s disease, showcasing the company’s dedication to addressing neurodegenerative disorders.
• RY104: A gene therapy initiative to treat age-related macular degeneration, underlining the company’s focus on combating blindness in the elderly.
• BIO-101: A preclinical stage HBV gene vaccine directed against hepatitis B, demonstrating the company’s commitment to preventing viral infections.
• RY105: A gene therapy designed to address liver fibrosis, showcasing REYON Pharmaceutical’s efforts in tackling liver diseases.
• GB102: Under development for the treatment of chronic kidney and coronary artery disease, reflecting the company’s dedication to addressing key areas of internal medicine.
• RY110: An iPSC-derived NK cell therapy targeting solid tumors, representing the company’s cutting-edge approach in cancer therapy.
• RY108: An antifungal drug currently in the preclinical study stage, showing the company’s commitment to broadening its infectious disease portfolio.
• RY106/RY107: A mRNA-based vaccine and gene therapy for anti-virus and rare genetic diseases, highlighting the company’s innovative approach in genetic medicine.
• RY109: A pDNA-based cancer vaccine for ovarian cancer, reflecting REYON Pharmaceutical’s ongoing efforts in the fight against cancer.

The company’s product line also spans adrenal corticosteroids, angiotensin II receptor antagonists, antibiotics, anticholinergics, antiemetics, antihypertensives, anti-inflammatory enzymes, antilipidemic, antirheumatic, oral hypoglycemic agents, anti-peptic ulcer drugs, antispasmodics, drugs for benign prostatic hypertrophy, cough and cold remedies, cardiac stimulants, genitourinary smooth muscle relaxants, hemostatics, immunosuppressants for rheumatoid arthritis, local anesthetics, migraine drugs, miscellaneous cardiovascular system drugs, neuromuscular disorder related drugs, nootropics and neurotonics, NSAIDs, respiratory stimulants, skeletal muscle relaxants, and vasodilators. This broad spectrum of offerings underlines REYON Pharmaceutical’s commitment to bringing comprehensive healthcare solutions to a global clientele.